Last reviewed · How we verify
NCT07427537: miR-CIPN#1
Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients
NA trial testing Assessment of blood concentrations of microRNAs in Cancer, Lung in 90 participants. Currently enrolling.
31 July 2028
Quick facts
| Lead sponsor | University Hospital, Clermont-Ferrand |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 90 |
| Start date | 29 January 2026 |
| Primary completion | 31 July 2028 |
| Estimated completion | 31 July 2028 |
| Sites | 1 location across France |
Drugs / interventions tested
- Assessment of blood concentrations of microRNAs
- Chemotherapy-induced peripheral neuropathy (CIPN) - grade
- Pain assessement
- Assessment of blood concentrations of neurofilament light chain
- Neuropathic pain assessment
- Chemotherapy-induced peripheral neuropathy (CIPN) - severity
Conditions studied
- Cancer, Lung — all drugs for Cancer, Lung →
- Colon Neoplasm — all drugs for Colon Neoplasm →
- Neuropathy;Peripheral — all drugs for Neuropathy;Peripheral →
Sponsor
University Hospital, Clermont-Ferrand
Who can join
18 and older, any sex, with Cancer, Lung or Colon Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07427537
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer, Lung
Currently open trials in the same condition.
- NCT05857995 — Precision Lung Cancer Survivorship Care Intervention · NA · recruiting
- NCT04300244 — Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma · Phase 2 · active not recruiting
Other University Hospital, Clermont-Ferrand trials
Trials by the same sponsor.
- NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
- NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
- NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
- NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting
- NCT07313865 — From Commensalism to Pathogenicity: Exploring the Pathophysiology of Bacteremia to Better Understand Enterococcus Faecal · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07427537 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
- Last refreshed: 23 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07427537.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing